|Other names||(11β, 16α)-16, 17-[[(R)-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21- (2-methyl-1-oxopropoxy)- pregna-1, 4-diene-3, 20-dione|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||540.697 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Ciclesonide is a glucocorticoid used to treat asthma and allergic rhinitis. It is marketed under the brand names Alvesco for asthma and Omnaris, Omniair, Zetonna, and Alvesco for hay fever in the US and Canada.
Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings.
It was patented in 1990 and approved for medical use in 2005. The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006. It is on the World Health Organization's List of Essential Medicines.
- "Covis Pharma – Products".
- Mutch E, Nave R, McCracken N, Zech K, Williams FM (May 2007). "The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue". Biochemical Pharmacology. 73 (10): 1657–64. doi:10.1016/j.bcp.2007.01.031. PMID 17331475.
- Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 488. ISBN 9783527607495.
- "FDA News Release. FDA Approves New Treatment for Allergies". Food and Drug Administration. 2006-10-23. Retrieved 2009-07-30.
- World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.